Macular degeneration drug approved

Share this article:

The Food and Drug Administration recently approved a drug for the treatment of the wet form of age-related macular degeneration. The medication is called Eylea. The medication is manufactured by Regeneron Pharmaceuticals. At $1,850 per injection, it costs $1000 less than Genentech's Lucentis. Macular degeneration is the leading cause of severe vision loss among residents in senior living settings.


Share this article:
close

Next Article in Products

More in Products

LeadingAge's CAST releases medication management tools

LeadingAge's Center for Aging Services Technologies release new tools last week to help long-term care providers identify the best medication management product.

Butler Mobility updates paint colors for platform lifts

Butler Mobility updates paint colors for platform lifts

Butler Mobility has widened the spectrum of paint color choices for its Incline Platform Lifts line.

NeuroMetrix releases pain management system

NeuroMetrix releases pain management system

NeuroMetrix Inc. has created the SENSUS™ Pain Management System, a wearable neurostimulation technology developed for chronic neuropathic pain, including painful diabetic neuropathy.